
Researchers at the University of Chicago have unveiled a whole‑body spatial transcriptomics method that slices frozen mice and maps gene expression across millions of cells in a single cross‑section. Using a cryomacrotome and 600,000 spatial spots, the technique captured activity of over 5,000 genes in 37 tissue sub‑regions after a bacterial toxin challenge. The approach promises to reveal organ‑wide drug effects and disease mechanisms that traditional single‑organ studies miss. While not single‑cell resolution, it represents a scale‑up of existing spatial sequencing technologies.

Researchers at UC San Diego introduced the MetALD‑ALD Prediction Index (MAPI), a biomarker panel that leverages routine blood tests to differentiate alcohol‑associated liver disease from metabolic steatotic liver disease. In a 503‑patient US cohort, MAPI achieved 60% sensitivity, 80% specificity,...

AstraZeneca announced that its investigational COPD antibody achieved positive results in two Phase 3 trials, marking a turnaround after a previous mid‑stage failure. The studies demonstrated statistically significant improvements in lung function and exacerbation rates across a broader patient population...
Human Longevity, Inc. and the LEV Foundation announced a strategic partnership to analyze blood samples from centenarians and supercentenarians. The collaboration will use HLI's AI‑driven precision longevity platform and LEV’s expertise in lifespan extension to uncover molecular drivers of exceptional...
Novo Nordisk announced that the U.S. Food and Drug Administration has approved Awiqli (insulin icodec-abae), the first and only once‑weekly basal insulin for adults with type 2 diabetes. The approval follows the ONWARDS phase 3a trial program involving roughly 2,680 patients and...

A preclinical study in Small describes an inulin‑butyrate nanogel that releases butyrate directly in the inflamed colon of mice, markedly improving colitis outcomes. The nanogel remains stable through the upper GI tract and is enzymatically activated by colonic microbes, delivering...
Hims & Hers announced it will stop actively marketing compounded GLP‑1 drugs and focus on a broader portfolio of FDA‑approved, branded GLP‑1s through a new partnership with Novo Nordisk. The pivot follows a 70% stock plunge and aims to sustain...

It was a pleasure to participate in the Investment and Innovation Pathways to a Healthy Asia session at the Global Investors’ Symposium in Hong Kong. A timely discussion on where durable value is being created in healthcare across Asia, from prevention...
The life of a chemist is about to change dramatically as we move away from tedious trial-and-error and deeper into the comfort of the prompt window. We don't need fewer medicinal chemists; we need more high-novelty drugs on the market...
A multidisciplinary team at Washington University in St. Louis implanted nanodiamond quantum sensors inside living mouse cells and recorded real‑time magnetic and temperature fluctuations from mitochondria. The breakthrough, presented at the March 16, 2026 APS meeting, demonstrates a new route...
Simulations Plus has launched strategic partnership programmes with three pharmaceutical companies to embed AI‑driven modelling into the drug development lifecycle. The collaborations will integrate Simulations Plus platforms—ADMET Predictor, GastroPlus, Thales and MonolixSuite—into model‑informed drug development (MIDD) workflows, enabling natural‑language interaction and automated...
Zhongzhi Pharmaceutical Holdings Limited announced a full‑year 2025 net profit of RMB17.29 million ($2.4 million), an 82% plunge from the previous year, while revenue dropped 21.5% to RMB1.737 billion ($243 million). The sharp contraction underscores growing pressure on Chinese drug makers amid a tightening...

The pharmaceutical industry faces commercial risk as it prepares for the 2033 transition to a uniform 12‑digit NDC format, with experts warning that thousands of zero‑prefix collisions could trigger PBM claim rejections, disrupt patient‑hub enrollments, and corrupt market‑intelligence data. Simultaneously,...

Soley Therapeutics, founded by clinician‑scientist Yerem Yeghiazarians and a cancer biologist, built a decade‑long, image‑based platform that treats cells as sophisticated sensors of their micro‑environment. The technology decodes how cells decide to live or die under low‑oxygen, nutrient‑poor conditions—an environment...

MIT researchers discovered that three widely used anesthetics—propofol, ketamine and dexmedetomidine—produce an identical destabilization of brain dynamics, measurable as a loss of dynamic stability. Using EEG‑based perturbation analysis, they showed that despite distinct molecular targets, each drug pushes the brain...

HaemaLogiX, an Australian clinical‑stage biotech, is developing precision immunotherapies for multiple myeloma by targeting novel antigens KMA and LMA that appear only on malignant plasma cells. Peer‑reviewed research validates these targets, allowing the company to spare healthy plasma cells and...

Novartis announced a definitive agreement to acquire Excellergy, a private biotech developing next‑generation anti‑IgE therapies. The deal values Excellergy at up to $2 billion in upfront and milestone payments, with closing targeted for the second half of 2026. Exl‑111, Excellergy’s lead...

Insilico Medicine and Tenacia Biotechnology have expanded their AI‑driven partnership to create a second central‑nervous‑system (CNS) candidate, now advancing to the preclinical stage. The original March 2025 collaboration combined Insilico’s Pharma.AI platform with Tenacia’s expertise in blood‑brain‑barrier‑permeable small‑molecule inhibitors. Under...

Abcuro presented Phase II/III MUSCLE trial data for ulviprubart (ABC008) in inclusion body myositis (IBM) at the GCOM 2026 meeting. The study enrolled 272 patients who received either 0.5 mg/kg, 2 mg/kg, or placebo. Across the entire cohort the drug showed only...

AstraZeneca’s experimental antibody tozorakimab cut moderate‑to‑severe COPD flare‑ups in two phase‑III trials, meeting its primary endpoint. The drug showed a statistically meaningful reduction across both current and former smokers, including those with varying lung damage. The positive data lifted AstraZeneca...

Georgia Tech’s Advanced Technology Development Center announced that two of its HealthTech portfolio companies, Nephrodite and OrthoPreserve, have each received the FDA’s Breakthrough Device designation. The program promises accelerated regulatory interaction, more frequent agency meetings, and priority review. Nephrodite’s solution...
The coolest meeting I had this week with was Paul, who used ChatGPT and other LLMs to create an mRNA vaccine protocol to save his dog Rosie. It is amazing story. "The chat bots empowered me as an individual to act...
Now imagine every cancer patient had access to this technology (they should) "A specifically designed mRNA vaccine - a precision-guided weapon to strike the cancer, developed with a pipeline designed by ChatGPT o1, implemented for candidate development by Gemini Pro 2,...

Innovent Biologics reported its first annual profit, propelled by strong demand for its weight‑loss medication. The Hong Kong‑listed company’s shares surged as much as 7.75%, the biggest jump since late October. The profit milestone underscores the rapid growth of China’s...
When we seeded Denali the idea was to break the curse of the blood/brain barrier. It took a decade and tons of faith and money. Biotech is hard. Curing diseases is hard. This is a good summary. ...

Efficacy of Alpha-Lipoic Acid in Patients With Ischemic Heart Failure: A Double-Blind, Randomized, Placebo-Controlled Study | @JACCJournals https://t.co/nW9SbwEDfy https://t.co/qsemjmMb9k
Vytrus Biotech SA announced full‑year earnings of €2.89 million, up 183% from the prior year, while revenue surged 66% to €8.37 million. The results highlight robust market demand for its pipeline and signal momentum for European biotech firms.

GLP-1 and the cardiovascular system "This Review summarizes the effects of GLP-1 and GLP-1RAs in the CV system..." https://t.co/Sy7Jjb96WD https://t.co/v3T01fIcOs

Billionaire-backed scientists aim to grow 'headless humans' to farm their organs... and help biohackers live for longer https://t.co/uQOzEtBapf https://t.co/HYZCMCOPy3

The FDA has granted approval to Rocket Pharma's gene therapy Kresladi for severe leukocyte adhesion deficiency type 1 (LAD‑1), an ultra‑rare immune disorder. The therapy was previously rejected in 2024 due to manufacturing concerns, but the agency cleared it after the...
GARM, operating as Longevity Advanced, announced the addition of the anti‑aging protein Klotho to its gene‑therapy portfolio at its Roatán clinic. The move broadens a suite that already includes Follistatin and VEGF, positioning the center as a hub for high‑end...
Great to see a new work showing that C1ORF112 is upregulated in tumor tissues and that it promotes breast cancer proliferation. We computationally predicted C1ORF112 to be related to cancer back in 2012, and we were the first to study and...

Scientists at Shenyang Pharmaceutical University have engineered eye drops using exosomes derived from pig semen, loaded with a carbon‑dot nanozyme, to breach the retinal barrier in mice. The formulation halted retinoblastoma tumor growth and preserved normal vision over a 30‑day...

Agenus announced a March 31, 2026 stakeholder webcast to detail progress on its botensilimab and balstilimab (BOT + BAL) immunotherapy program. The company highlighted clinical durability across multiple tumor types, with roughly 1,200 patients treated with botensilimab and over 900 with balstilimab...

Clarity Pharmaceuticals has signed a manufacturing supply agreement with Theragenics to scale up production of copper‑64, a radiometal used in its investigational prostate‑cancer tracer 64Cu‑SAR‑bisPSMA. The deal leverages Theragenics’ Atlanta‑area facility, which houses 14 cyclotrons capable of producing roughly 100...
Rice University researchers have engineered a synthetic origin of replication that lets scientists control plasmid copy number and avoid incompatibility by using custom RNA control elements. The modular design was validated by co‑expressing six different plasmids in a single bacterial...
Researchers at Helmholtz‑Zentrum Hereon and partners propose a payload‑driven approach to nucleic‑acid delivery, designing polymeric carriers that are chemically tuned to each DNA, RNA or mRNA payload. The strategy contrasts with the one‑size‑fits‑all lipid nanoparticles that dominate current vaccines and...
LeonaBio announced it has secured an exclusive global license for the Phase 3 lasofoxifene program, a novel selective estrogen receptor modulator aimed at ESR1‑mutated metastatic breast cancer, and raised $90 million in a private placement that could expand to $236 million with warrant...

Colossal Biosciences, the company aiming to resurrect the woolly mammoth through genetic engineering, has spun out its artificial‑intelligence venture Astromech. The new startup, founded by Colossal co‑founders Ban Lamm and renowned geneticist George Church, secured a $2 billion valuation, making it...
Frank Harrell, a former FDA statistician, responded to recent JAMA commentary on the agency’s draft guidance promoting Bayesian methods for clinical trials. He highlighted that while the guidance is a step forward, FDA reviewers still rely on traditional frequentist approaches...
New Paper - Evidence suggests regeneration may be a natural and achievable biological process worth prioritizing over merely slowing aging—ideally beginning in midlife (around 40–60) to postpone decline, with the potential to reverse aging later in older individuals. Insights from...

This week's @TheLancet cover and editorial about getting GLP-1 drugs available for the people who need them the most https://t.co/BU9NZdmdGo https://t.co/TWOIKvfuth
Jiangsu Hengrui Medicine announced 2025 results showing a 13% jump in revenue to RMB 31.63 billion ($4.4 billion) and a 21.8% rise in net profit to RMB 7.72 billion ($1.1 billion). The surge was powered by strong innovative‑drug sales and a landmark Hong Kong...
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD

A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/ejA8KSoxOL
Neion Bio, fresh from stealth mode, signed its first co‑development and supply agreement with a major global pharmaceutical company to produce recombinant biologics using its egg‑based Raptor™ platform. The deal provides upfront and milestone payments plus profit‑sharing after commercialization, delivering...

Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] @bdermanmd @jagoda_jasielec @ajjakubowiak Brit J Haematol https://t.co/8zhxYfYwZQ #mmsm #mmMRD https://t.co/lbZ4AFZ1YM
What a joy to chat with my old friend Rob Califf @DrCaliff_FDA about the FDA under his leadership, the FDA today, AI regulation, misinformation, clinical research & more. We also discussed his memories of being a @UCSF medicine resident back...
A “kazarian?” Is that like a Kardashian? What planet are these X trolls from? I develop low-cost often patent-free vaccines for global health and to help humanity. So far 100 million have benefited from access to our vaccine technologies developed...